Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340621 | 0.92 | MCL1 (0.52) | TDO2MCL1RAD51IDO1LRRK2 | |
| SCHEMBL17102969 | 0.90 | MAOA (0.51) | TDO2MCL1RAD51CYP11B2MAOA | |
| SCHEMBL17102971 | 0.88 | MAOA (0.53) | TDO2MCL1RAD51CYP11B2MAOA | |
| SCHEMBL20340626 | 0.85 | TDO2 (0.51) | TDO2MCL1RAD51CYP1A2IDO1 | |
| SCHEMBL17122539 | 0.78 | MCL1 (0.47) | MCL1CYP1A2CYP2C19CYP2A6 | |
| SCHEMBL17517555 | 0.77 | TDO2 (0.49) | TDO2MCL1CYP1A2CYP2C19CYP2A6 | |
| SCHEMBL20340627 | 0.76 | MCL1 (0.50) | MCL1MAOAMAOBACHE | |
| SCHEMBL27910573 | 0.76 | MCL1 (0.53) | MCL1 | |
| SCHEMBL20340633 | 0.74 | MCL1 (0.50) | MCL1CYP1A2CYP2C19CYP2A6MAOA | |
| SCHEMBL17517534 | 0.74 | MCL1 (0.47) | MCL1MAOAMAOBACHETBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | BRCA1, CA7, DCK | TDO2 3232/4885MCL1 205/4885RAD51 1752/4885 |
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | BRCA1, CA7, DCK | TDO2 3274/4885MCL1 209/4885RAD51 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.